Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009